General Information of Drug (ID: DMQ9317)

Drug Name
GEN1044 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMQ9317

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TroVax DMHDNK0 Prostate cancer 2C82.0 Phase 3 [3]
Naptumomab estafenatox DM901ZW Solid tumour/cancer 2A00-2F9Z Phase 2/3 [4]
CV-9201 DMCPZYT Non-small-cell lung cancer 2C25.Y Phase 1/2 [5]
PF-06263507 DM5KBDY Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
IM1240 DMTV0DK Aggressive cancer 2A00-2F9Z Preclinical [7]
Anatumomab mafenatox DMMLDG8 Breast cancer 2C60-2C65 Terminated [8]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [9]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [10]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [11]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [12]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [13]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [14]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [15]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [16]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [17]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oncotrophoblast glycoprotein 5T4 (TPBG) TT70MLA TPBG_HUMAN Not Available [2]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [2]

References

1 ClinicalTrials.gov (NCT04424641) A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of AbbVie.
3 Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
4 Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
5 National Cancer Institute Drug Dictionary (drug id 648549).
6 National Cancer Institute Drug Dictionary (drug id 751006).
7 Clinical pipeline report, company report or official report of Purple
8 A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.
9 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
10 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
11 Clinical pipeline report, company report or official report of Genmab.
12 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
13 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
14 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
15 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
16 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
17 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
18 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.